GRASTOFIL

This brand name is authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug GRASTOFIL contains one active pharmaceutical ingredient (API):

1	Filgrastim UNII PVI5M0M1GW - FILGRASTIM
	Filgrastim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
	Read more about Filgrastim

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA02	Filgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02441489, 02454548
EE	Ravimiamet	1630448, 1630583, 1630594, 1630606
FR	Base de données publique des médicaments	60169147, 62635483
IE	Health Products Regulatory Authority	88184, 88188
IT	Agenzia del Farmaco	043068016, 043068028, 043068030, 043068042
LT	Valstybinė vaistų kontrolės tarnyba	1071754, 1071755, 1071756, 1071757
PL	Rejestru Produktów Leczniczych	100157968, 100286022